Clinical Trials Browser

Unknown × OTHER × atezolizumab × Clear all

NCT04739670 2024-03-01

BELLA

Phase 2 Unknown

Recurrence, Triple Negative Breast Neoplasms

NCT05173298 2024-02-07

HCC

Gastrointestinal

Carcinoma, Hepatocellular

NCT05266937 2024-02-01

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05833126 2023-12-15

Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

Phase 2 Unknown

Recurrent Liver Cancer After Liver Transplantation

NCT05259319 2023-10-17

IMMUNOs-SBRT

Phase 1 Unknown

GenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03818061 2023-09-28

ATHENA

Phase 2 Unknown

Head and Neck Neoplasms

NCT05418660 2023-09-18

I-STOP

Carcinoma, Non-Small-Cell Lung

NCT04659382 2023-08-18

SIRTCI

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT03363867 2023-08-07

BEACON

Phase 2 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05886465 2023-06-02

HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT03991403 2023-04-03

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03654833 2023-03-14

MiST

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT05038657 2022-10-03

AURORA

Phase 2 Unknown

Carcinoma, Squamous Cell, Urologic Neoplasms

NCT05396937 2022-05-31

Efficacy and Safety of T+A+RAD in HCC

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05034055 2021-09-05

SKYROCKET

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04465942 2021-08-23

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Carcinoma, Non-Small-Cell Lung

NCT04739202 2021-03-29

IMMUNOGAST

Phase 2 Unknown

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04696939 2021-01-06

Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung

NCT03647956 2019-04-17

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03620435 2018-08-13

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

Phase 2 Unknown

Safety Issues

NCT03616691 2018-08-06

Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03228368 2017-07-24

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

Carcinoma, Non-Small-Cell Lung